Kamada (NASDAQ:KMDA) Shares Pass Below Two Hundred Day Moving Average - What's Next?

Key Points

• Kamada Ltd. shares dropped below their 200-day moving average, trading at $6.88, indicating a potential shift in investor sentiment.
• Analysts have a consensus rating of "Moderate Buy" for Kamada, with an average target price of $13.00, despite the recent price decline.
• The company reported earnings of $0.13 per share, exceeding estimates, but revenue fell significantly short of expectations at $44.75 million compared to $158.59 million.

Kamada Ltd. (NASDAQ:KMDA - Get Free Report) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $7.00 and traded as low as $6.75. Kamada shares last traded at $6.88, with a volume of 42,576 shares.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a "buy (b-)" rating on shares of Kamada in a report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Kamada has a consensus rating of "Moderate Buy" and an average target price of $13.00.

Kamada Trading Up 1.2%

The company has a 50 day moving average price of $7.00 and a 200 day moving average price of $7.00. The firm has a market cap of $395.67 million, a PE ratio of 20.24, a price-to-earnings-growth ratio of 0.69 and a beta of 0.84.

Kamada (NASDAQ:KMDA - Get Free Report) last released its quarterly earnings results on Wednesday, August 13th. The biotechnology company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.04. Kamada had a return on equity of 7.41% and a net margin of 11.22%.The company had revenue of $44.75 million during the quarter, compared to the consensus estimate of $158.59 million. Kamada has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Kamada Ltd. will post 0.23 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kamada

Several hedge funds have recently modified their holdings of the company. Trexquant Investment LP purchased a new stake in shares of Kamada during the first quarter worth about $82,000. Cubist Systematic Strategies LLC purchased a new stake in Kamada in the 1st quarter worth approximately $206,000. Jump Financial LLC purchased a new stake in Kamada in the 2nd quarter worth approximately $219,000. NewEdge Advisors LLC lifted its stake in shares of Kamada by 119.9% during the 1st quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company's stock worth $341,000 after purchasing an additional 28,165 shares during the period. Finally, Arrowstreet Capital Limited Partnership purchased a new position in shares of Kamada during the 2nd quarter worth $472,000. 20.38% of the stock is owned by institutional investors and hedge funds.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.